ThromboGenics to present THR-317 Pre-clinical Research Findings at the European Association for the Study of Diabetes, Eye Complications Study Group (EASDec) Meeting in Budapest, Hungary
Go back to ThromboGenics to present THR-317 Pre-clinical Research Findings at the European Association for the Study of Diabetes, Eye Complications Study Group (EASDec) Meeting in Budapest, Hungary| THERMON GROUP HOLDINGS, Inc. (NYSE: THR) | Delayed: 61.14 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $61.14 | 52 Week High | $21.87 | |||
| Open | $61.14 | 52 Week Low | $13.97 | |||
| Day High | $61.14 | P/E | 91.25 | |||
| Day Low | $61.14 | EPS | $0.67 | |||
| Volume | 116,188 | |||||
